 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- ulenistamab (PBP1510) / Prestige BioPharma
PBP1510, a novel monoclonal antibody targeting pancreatic adenocarcinoma upregulated factor (PAUF): Phase 1/2a monotherapy and combination with gemcitabine in patients with advanced/metastatic pancreatic cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5279;
P1/2
The next monotherapy (PBP1510, 6 mg/kg) and combination (PBP1510, 1 mg/kg; gemcitabine 1000 mg/m2) cohorts are open for recruitment. Clinical trial information: NCT05141149.
- || ulenistamab (PBP1510) / Prestige BioPharma
Trial completion date, Trial primary completion date, Metastases: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer (clinicaltrials.gov) - Apr 19, 2024
P1/2, N=80, Recruiting, Sponsor: Prestige Biopharma Limited
- ulenistamab (PBP1510) / Prestige BioPharma
A first-in-human phase 1/2a study of a novel anti-PAUF monoclonal antibody PBP1510 in patients with advanced/metastatic pancreatic cancer (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_3882;
Clinical trial information: NCT05141149. Abstract is embargoed at this time.
- || ulenistamab (PBP1510) / Prestige BioPharma
Trial completion date, Trial primary completion date, Metastases: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer (clinicaltrials.gov) - Sep 15, 2023
P1/2, N=80, Recruiting, Sponsor: Prestige Biopharma Limited
Abstract is embargoed at this time. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
- ulenistamab (PBP1510) / Prestige BioPharma
PAUF as a target for treatment of high PAUF-expressing ovarian cancer () - Jul 27, 2023 - Abstract #ESMO2023ESMO_1679;
Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Feb 2026 Treatments (started from day 0): Human IgG (control), Anti-PAUF antibody (10 mg/kg, twice/week,
- ||| ulenistamab (PBP1510) / Prestige BioPharma
Enrollment open, Trial completion date, Trial primary completion date, Metastases: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer (clinicaltrials.gov) - May 6, 2023
P1/2, N=80, Recruiting, Sponsor: Prestige Biopharma Limited
Treatments (started from day 0): Human IgG (control), Anti-PAUF antibody (10 mg/kg, twice/week, Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2024
- || ulenistamab (PBP1510) / Prestige BioPharma
Trial primary completion date, Metastases: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer (clinicaltrials.gov) - Feb 8, 2023
P1/2, N=80, Not yet recruiting, Sponsor: Prestige Biopharma Limited
Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2024 Trial primary completion date: Mar 2023 --> Sep 2023
- | ulenistamab (PBP1510) / Prestige BioPharma
#PrestigeBiopharma Obtains #PBP1510 #Patent in Indonesia, Marking the Tenth https://t.co/yzTBoPvwtm (Twitter) - Nov 11, 2022
- ulenistamab (PBP1510) / Prestige BioPharma
A clinical study assessing ZG16B/PAUF overexpression in high-grade ovarian serous adenocarcinoma () - Oct 23, 2022 - Abstract #ESGE2022ESGE_1005;
P1/2
Recently, a new anti-PAUF/ZG16B antibody, PBP1510, was developed by PrestigeBiopharma (NCT05141149). This study provides arguments in support of a future clinical trial to evaluate this antibody in patients with ovarian cancer.
- || ulenistamab (PBP1510) / Prestige BioPharma
Trial primary completion date, Metastases: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer (clinicaltrials.gov) - Sep 28, 2022
P1/2, N=80, Not yet recruiting, Sponsor: Prestige Biopharma Limited
This study provides arguments in support of a future clinical trial to evaluate this antibody in patients with ovarian cancer. Trial primary completion date: Oct 2022 --> Mar 2023
- ulenistamab (PBP1510) / Prestige BioPharma
First-in-class monoclonal antibody (mAb) PBP1510 targeting pancreatic adenocarcinoma upregulated factor (PAUF) for pancreatic cancer (PC) treatment: Preclinical perspectives. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_2183;
The efficacy and safety data presented here, along with the data from in vivo mouse studies demonstrating superior anti-tumour activity of PBP1510 treatment, support further clinical development of PBP1510 as a novel anti-cancer agent to treat PAUF-positive PC. The pivotal step of advancing PBP1510 into initial human studies is now in progress.
- || ulenistamab (PBP1510) / Prestige BioPharma
Trial initiation date, Metastases: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer (clinicaltrials.gov) - Apr 22, 2022
P1/2, N=80, Not yet recruiting, Sponsor: Prestige Biopharma Limited
The pivotal step of advancing PBP1510 into initial human studies is now in progress. Initiation date: Jan 2022 --> May 2022
- PBP1510 / Prestige BioPharma
Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb) ([VIRTUAL]) - Dec 6, 2021 - Abstract #ESMOTAT2022ESMO_TAT_67;
As a result, PBP1510 was granted Orphan Drug Designation by EMA, US FDA and Korea MFDS. The pivotal step of advancing PBP1510 into initial human studies is now in progress.
- |||| ulenistamab (PBP1510) / Prestige BioPharma
New P1/2 trial, Metastases: First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients with Pancreatic Cancer (clinicaltrials.gov) - Dec 2, 2021
P1/2, N=80, Not yet recruiting, Sponsor: Prestige Biopharma Limited